Century Therapeutics price target lowered to $2 from $4 at Piper Sandler

Piper Sandler analyst Edward Tenthoff lowered the firm’s price target on Century Therapeutics (IPSC) to $2 from $4 and keeps an Overweight rating on the shares. Century will dose the first autoimmune disease patient in the Phase I CALiPSO-1 study of CD19 CAR-iNK CNTY-101 this month with initial data in 2025, the firm notes. Piper also highlights that Century discontinued the Phase I ELiPSE-1 study in r/rNHL to focus resources on autoimmune disease.